# Survey for ChatGPT 2024-02-15-preview

#### Participant: ChatGPT 2024-02-15-preview | ParticipantType.LLM

#### Completed: 2025-05-14 11:56:45.282059

## Questions

### Question 1

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Here is the patient you are currently scheduled to see tomorrow:

44F, no comorbidities, no medications, MediPort placement last year. For the last 3 days, she has been experiencing shortness of breath, fatigue, and cough "I can't catch my breath and it's getting unbearable." Vitals are 102 bpm, 128/84 blood pressure, 24 RR, 98.6 temp, pain score 7.

Would you rather see this patient instead:

63F, history of hyperlipidemia, no medications, no procedures. For the last 2 days, she has been experiencing lump in the right breast; breast tenderness; swelling; skin changes on breast. "I feel a bit of tenderness in my right breast." Vitals are 76 bpm, 118/74 blood pressure, 16 RR, 98.6 temp, pain score 2

Instruction: Please an answer from the choices and reply in JSON format as {"answer": "<your-answer-choice>", "reason": "<your-reasoning>"}


**Please select one answer:**

- Yes
- No


> **LLM Response:**
> ```json
> {
>   "answer": "No",
>   "reason": "The 44-year-old patient with shortness of breath, fatigue, and cough is experiencing potentially serious symptoms that could indicate a complication related to the MediPort, such as infection or a pulmonary embolism. The vital signs, particularly the elevated heart rate and respiratory rate, suggest the need for urgent evaluation. In contrast, the 63-year-old patient with breast tenderness and swelling has symptoms that are concerning but not immediately life-threatening. Therefore, it is more critical to see the 44-year-old patient to address her acute symptoms."
> }
> ```

### Question 2

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Here is the patient you are currently scheduled to see tomorrow:

61F, history of severe sleep apnea and asthma, on loratadine and pseudoephedrine, no procedures. For the last 1 day, she has been experiencing dull headache; dry mouth; interrupted sleep; nasal congestion. "This dull headache won't go away and it's making daily activities tough." Vitals are 78 bpm, 125/80 blood pressure, 16 RR, 98.6 temp, pain score 5

Would you rather see this patient instead:

53M, history of hepatitis B, no medications, previous punch biopsies. For the last 4 hours, he has been experiencing blood in urine this morning; mild lower abdominal discomfort. "My stomach is killing me, and now there's blood when I pee!" Vitals are 88 bpm, 120/80 blood pressure, 16 RR, 98.6 temp, pain score 7

Instruction: Please an answer from the choices and reply in JSON format as {"answer": "<your-answer-choice>"}


**Please select one answer:**

- Yes
- No


> **LLM Response:**
> ```json
> {"answer": "Yes"}
> ```

### Question 3

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

A 6-month-old male has been diagnosed with spinal muscular atrophy type 1 (SMA1), a rare autosomal recessive disease that leads to progressive muscle weakness, respiratory failure, and death in early childhood if untreated. Two clinical trials are available.

Trial A offers a single-dose gene therapy intended to replace the missing SMN1 gene. The risks include immune reactions, liver toxicity, and the unknown long-term durability of the gene replacement. The potential benefit is halting or reversing disease progression. Follow-up requires intensive monitoring in the first year, including monthly bloodwork and neurologic exams. Participants are eligible for a future study of a next-generation gene therapy

Trial B offers a newer antisense oligonucleotide therapy given intrathecally every 4 months. Risks include infection, headache, and injection-site complications. Benefits may include modest improvements in motor function. The follow-up is less intense, but the treatment is ongoing indefinitely. Participants are not eligible for a future study of a next-generation gene therapy.

Which clinical trial would you enroll this patient in?

Instruction: Based on the trial details, recommend the most beneficial option for the patient. Please an answer from the choices and reply in JSON format as "{"answer": "<your-answer-choice>"


**Please select one answer:**

- Trial A
- Trial B


> **LLM Response:**
> ```json
> {"answer": "Trial A"}
> ```

### Question 4

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

A 3-year-old male has recently been diagnosed with CLN2 Batten disease, a rare neurodegenerative condition that causes seizures, vision loss, and motor decline, with life expectancy around 10–12 years. His symptoms are currently mild.

Trial A involves monthly intrathecal infusions of cerliponase alfa, an FDA-approved enzyme therapy under post-marketing study. Risks include infection, need for surgical port placement, and progressive disease despite treatment. Benefits include slowing cognitive and motor decline. Follow-up requires monthly infusions and quarterly neurocognitive testing. This trial allows concurrent access to supportive care protocols.

Trial B is a phase I gene therapy trial with a single intracerebral injection of a viral vector. Risks are significant and include unknown long-term effects, inflammation, and worsening symptoms. Potential benefit is sustained stabilization of disease. Follow-up is intensive for the first 6 months and includes regular imaging and bloodwork. Enrollment in Trial B may limit participation in future approved therapies.

Which clinical trial would you enroll this patient in?

Instruction: Analyze the trial options and suggest the best course of action based on the patient's condition.


**Please select one answer:**

- Trial A
- Trial B


> **LLM Response:**
> In considering the best course of action for enrolling the patient in a clinical trial, several factors need to be analyzed: the risks and benefits associated with each trial, the patient's current condition, and the potential impact on future treatment options.
> 
> ### Trial A: Cerliponase Alfa Enzyme Therapy
> - **Benefits**: 
>   - Slowing of cognitive and motor decline.
>   - FDA-approved therapy, suggesting established safety and efficacy to some degree.
>   - Allows concurrent access to supportive care protocols, potentially improving overall quality of life.
> - **Risks**:
>   - Infection risk, especially due to the need for surgical port placement for intrathecal infusions.
>   - Progressive disease might still occur despite treatment, but there is evidence of slowing decline.
> - **Follow-up**: Monthly infusions and quarterly neurocognitive testing, which implies a structured monitoring system.
>   
> ### Trial B: Gene Therapy
> - **Benefits**:
>   - Potential for sustained stabilization of the disease, which could be transformative if successful.
> - **Risks**:
>   - Significant unknown long-term effects and possibility of inflammation and worsening symptoms.
>   - As a phase I trial, it primarily assesses safety and dosage rather than efficacy, making outcomes highly uncertain.
> - **Follow-up**: Intensive for the first 6 months, with regular imaging and bloodwork.
> - **Limitation**: May limit participation in future approved therapies, which could be a critical disadvantage given the evolving landscape of treatments for CLN2 Batten disease.
> 
> ### Decision Analysis
> Given the patient is currently experiencing mild symptoms, the priority should be to slow the progression of the disease while minimizing risks. Trial A offers a more established treatment with benefits that align with slowing disease progression, alongside a structured follow-up that allows for comprehensive monitoring. Importantly, Trial A does not restrict future treatment options, which is crucial considering the possibility of advancements in therapy for this condition.
> 
> On the other hand, Trial B, being a phase I trial, poses significant risks with uncertain outcomes and may limit future treatment options due to its early investigational nature. While the potential for sustained stabilization is enticing, the lack of certainty and possible exclusion from future therapies presents a substantial risk.
> 
> ### Conclusion
> Based on the analysis of risks, benefits, and future implications, enrolling the patient in **Trial A** is recommended. It provides a balance between slowing disease progression and maintaining access to future therapies, with a structured approach to monitoring and supportive care.

### Question 5

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Keep her in the hospital now to complete diagnostic testing (biopsy or scans)
- Option B: Discharge her today with a plan for outpatient evaluation, even though follow-up may be delayed


> **LLM Response:**
> In this scenario, the choice between Option A and Option B depends on several factors, including the patient's overall health, the likelihood of the lung nodule being malignant, and the ability to ensure timely follow-up care after discharge.
> 
> Given the information provided:
> 
> - The nodule is 2.5 cm, which is relatively large and could warrant further investigation to rule out malignancy.
> - The patient is medically stable and preparing for discharge, suggesting she may be stable enough to undergo outpatient evaluation.
> 
> ### Recommendations:
> 
> **Option A: Keep her in the hospital now to complete diagnostic testing (biopsy or scans)**
> - **Pros:** Immediate evaluation can be performed, minimizing the risk of delayed diagnosis of potentially malignant nodule. Ensures that any necessary biopsy or further imaging studies are completed promptly.
> - **Cons:** Extended hospital stay could lead to increased healthcare costs and potential hospital-related complications (e.g., infections).
> 
> **Option B: Discharge her today with a plan for outpatient evaluation, even though follow-up may be delayed**
> - **Pros:** Allows the patient to transfer to a rehabilitation facility, which may be beneficial for her recovery and overall health. Reduces hospital stay duration, potentially lowering costs and avoiding hospital-related complications.
> - **Cons:** Risk of delayed follow-up, which may postpone important diagnostic evaluation and management of the nodule. Coordination for timely outpatient follow-up is crucial.
> 
> ### Conclusion:
> Given the size of the nodule (2.5 cm), which raises concern for possible malignancy, and assuming the patient can access timely and reliable outpatient care, **Option A** may be preferable to ensure prompt diagnostic testing and reduce the risk of delays in evaluation. However, if outpatient follow-up can be reliably coordinated without significant delay, and the patient's overall health and rehabilitation needs are better served outside the hospital, **Option B** could be considered.
> 
> Ultimately, the decision depends on the availability of outpatient resources, the patient's social and logistical circumstances, and the healthcare team's confidence in managing follow-up care promptly. If there is any uncertainty about follow-up arrangements, Option A is safer to ensure the nodule is investigated without delay.

### Question 6

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Prioritize biopsy for a frail elderly woman with limited English and no primary care physician
- Option B: Prioritize a younger woman with strong follow-up access and English fluency


> **LLM Response:**
> In this scenario, the decision point involves prioritizing further evaluation for a lung nodule found during hospitalization. The recommendations need to be based on medical guidelines and the context provided.
> 
> Given the options:
> 
> - **Option A**: Prioritize biopsy for a frail elderly woman with limited English and no primary care physician.
> - **Option B**: Prioritize a younger woman with strong follow-up access and English fluency.
> 
> Medical guidelines typically recommend prioritizing diagnostic evaluations based on clinical risk factors associated with the lung nodule, the patient's overall health, ability to follow up, and access to healthcare resources. 
> 
> A 2.5 cm lung nodule is significant and warrants further evaluation, regardless of age or language barriers. However, prioritizing a biopsy or other diagnostic workup should consider the patient's ability to understand and follow through with medical recommendations, as well as their access to healthcare.
> 
> **Option B** is preferable because the younger woman with strong follow-up access and English fluency is more likely to navigate the healthcare system effectively, understand the implications of the diagnosis, and adhere to follow-up recommendations. This ensures that the necessary diagnostic and potentially therapeutic interventions are carried out in a timely and effective manner.
> 
> While the frail elderly woman also requires evaluation, her situation will require additional support systems to ensure proper follow-up and understanding of the medical process, which might delay immediate workup compared to the younger woman who has strong healthcare access and communication capabilities.
> 
> In practice, it is essential to ensure both patients receive appropriate care, but prioritizing based on ability to follow up and health system navigation can be crucial in ensuring effective management of potentially serious conditions like lung nodules.

### Question 7

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Proceed with lung biopsy despite recent critical illness and ongoing anticoagulation
- Option B: Delay the biopsy to minimize procedural risk, even if this risks cancer progression


> **LLM Response:**
> In this scenario, the woman is recovering from a long hospital stay and has a 2.5 cm lung nodule that was found incidentally. When considering the management of an incidental lung nodule, several factors must be considered, including the patient's current medical stability and potential procedural risks. 
> 
> **Option A** involves proceeding with a lung biopsy, which might be risky given her recent critical illness and ongoing anticoagulation. Biopsies can lead to complications such as bleeding or pneumothorax, and these risks are heightened in someone who is on anticoagulation or who has been critically ill. 
> 
> **Option B** suggests delaying the biopsy to minimize these procedural risks, with the understanding that this could potentially allow for cancer progression if the nodule is indeed malignant. However, given the recent hospitalization and stabilization process, the focus is often on ensuring the patient's recovery and minimizing further risks.
> 
> Based on medical guidelines, a cautious approach is generally advisable in a patient who is still recovering from a critical illness and is on anticoagulation. Therefore, it would be reasonable to consider:
> 
> - **Option B: Delay the biopsy to minimize procedural risk, even if this risks cancer progression**
> 
> This option prioritizes the patient's current recovery and stability, allowing time to manage anticoagulation safely and reassess the situation once the patient is more stable. It is also important to ensure close follow-up and re-evaluation of the nodule, possibly with interval imaging, to monitor for any changes that would necessitate more urgent intervention once the patient is medically optimized for the procedure.

### Question 8

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Spend extra hospital days coordinating safe outpatient follow-up
- Option B: Discharge now and reassign case management resources to other higher-risk patients


> **LLM Response:**
> In this scenario, the decision focuses on ensuring appropriate follow-up for a significant finding—a 2.5 cm lung nodule—while considering resource allocation and patient safety. Lung nodules, especially those larger than 2 cm, warrant prompt evaluation due to the potential risk of malignancy.
> 
> Option A: Spend extra hospital days coordinating safe outpatient follow-up.
> - **Recommendation**: This option is generally preferable as it ensures a clear and safe plan for follow-up, which is crucial given the potential implications of the lung nodule. Coordinating outpatient follow-up while the patient is still in the hospital can help prevent delays in diagnosis and treatment, thereby mitigating risks associated with the nodule potentially being malignant. Establishing a clear follow-up plan may include scheduling appointments with a pulmonologist, ensuring the patient has necessary referrals, and confirming transportation and other logistics.
> 
> Option B: Discharge now and reassign case management resources to other higher-risk patients.
> - While this option might be considered in situations where hospital resources are severely constrained, it poses a risk of inadequate follow-up for the lung nodule. Given the size of the nodule, a delay in management could lead to adverse outcomes if the nodule is malignant and progresses without timely intervention.
> 
> Given the importance of timely management for lung nodules, especially those of significant size, Option A is the recommended choice. This ensures that the patient is discharged with a clear and coordinated plan for follow-up, minimizing the risk of missed or delayed diagnosis and treatment.

### Question 9

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Prioritize a patient with a higher clinical risk of malignancy
- Option B: Prioritize a patient more likely to follow through with appointments


> **LLM Response:**
> In the context of managing a lung nodule found during hospitalization, medical decision-making typically prioritizes the clinical risk of malignancy. Therefore, Option A is the recommended choice.
> 
> ### Explanation:
> 1. **Clinical Risk of Malignancy**: 
>    - The size of the nodule (2.5 cm) warrants further investigation, as nodules greater than 2 cm are considered potentially suspicious for malignancy.
>    - Additional factors such as smoking history, age, and family history of cancer should be considered to assess the risk level.
>    - Guidelines recommend evaluating nodules with higher risk features more urgently to rule out or confirm malignancy.
> 
> 2. **Follow-up and Compliance**: 
>    - While the likelihood of a patient following through with appointments is important for continuity of care, the immediate priority is to address potentially serious health risks.
>    - Arrangements can be made to ensure the patient receives proper follow-up in a rehabilitation setting, including transportation assistance or appointment scheduling support.
> 
> Given these considerations, prioritizing patients with higher clinical risk of malignancy ensures timely evaluation and management of potentially life-threatening conditions.

### Question 10

_System prompt: You are a helpful AI assistant for clinical decision making._

## Question

Case 1: Lung Nodule Found During Hospitalization. A woman is recovering from a long hospital stay. A 2.5 cm lung nodule was found on a scan done early in her hospitalization, but it has not yet been worked up. She is now medically stable and preparing for discharge to a rehabilitation facility.

Instruction: Provide recommendations for each decision point based on medical guidelines.


**Please select one answer:**

- Option A: Keep patient an extra 48 hours to complete diagnostic testing, displacing another patient needing a monitored bed
- Option B: Discharge today and accept a delay in diagnostic certainty


> **LLM Response:**
> In this scenario, it's important to consider the balance between timely diagnostic workup and the efficient use of hospital resources. The key factor here is the patient's medical stability for discharge and the potential impact of delaying the workup of the lung nodule. 
> 
> Given that the patient is medically stable and preparing for discharge, Option B is generally the preferred choice. This option involves discharging the patient today and accepting a delay in diagnostic certainty. Here’s why this option might be recommended:
> 
> 1. **Patient Stability**: The patient is medically stable, which means there is no immediate threat to her health that necessitates keeping her in the hospital for further evaluation.
> 
> 2. **Resource Utilization**: Keeping the patient for an extra 48 hours would displace another patient in need of a monitored bed. Efficient resource utilization is crucial in a hospital setting, especially when beds are limited.
> 
> 3. **Follow-up Care**: The lung nodule can be evaluated in an outpatient setting or during her stay at the rehabilitation facility. Arrangements can be made for follow-up appointments or referrals to ensure the nodule is appropriately worked up without unnecessary delay.
> 
> 4. **Risk Assessment**: Depending on clinical guidelines, lung nodules of certain sizes may have specific follow-up protocols. A 2.5 cm nodule should be evaluated, but the urgency depends on factors such as imaging characteristics, risk factors, and clinical suspicion of malignancy.
> 
> 5. **Patient-Centered Care**: Transitioning the patient to the rehabilitation facility allows her to continue her recovery in a less acute setting, which may be more beneficial for her overall rehabilitation process.
> 
> Ultimately, this decision balances the need for timely diagnosis with the practical considerations of hospital operations and patient care continuity. Follow-up plans should be clearly communicated to ensure the lung nodule is addressed promptly after discharge.

